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Abstract
Background: Inherited metabolic diseases (IMD) are complex medical conditions. Thanks to improvements in
diagnosis and treatment, a growing number of pediatric IMD patients reach adulthood. Thus, clinical care of adults
with IMD has emerged as a new and challenging reality. This purpose of this study of adults with IMD in an adult
metabolic clinic at two academic hospitals (Lausanne and Geneva) was to help inform decisions on the future
organization of health care for this group of patients.
Methods: All adult patients with a biochemical and/or genetic diagnosis of IMD followed at the clinics were
included in the study. Electronic patient records were reviewed for clinical features, diagnostic studies, treatment
and long-term outcome. Data of undiagnosed patients referred for suspected IMD were analyzed separately.
Results: 126 patients were included in the study. The most prevalent group of diseases was small molecules
disorders with 82 (65%) patients, followed by energy defects disorders with 29 (23%) patients and complex
molecules disorders with 15 (12%) patients. Overall, 64% of patients were diagnosed before, and 36% after the age
16 years. Among the 126 cases, 51% suffered from medical complications. 79% of the patients were receiving a
specific treatment for their disease. Among the 138 undiagnosed patients referred for suspicion of IMD,
investigations lead to a genetic diagnosis in 24 (17%) patients. 19 had confirmation of an IMD, 5 were found to
have another genetic condition.
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Conclusions: This retrospective study reveals significant features of adult IMD cohort. The disorders are
heterogeneous, and there is no one-size-fits-all approach – treatment must be tailored to fit each specific disorder
in each individual patient. Even patients who are followed at the dedicated clinic are not protected from metabolic
decompensations and/or chronic organ-specific complications. While it is commonly assumed that patients with
IMD are more stable once they become adults, our data show that the diseases continue to exact a lifelong toll. A
coordinated monitoring of target organs by a multidisciplinary team is needed. To ensure that the success in
diagnosis and treatment of individuals with IMD is sustained, there is a clear requirement for adequately staffed
adult IMD clinics.
Keywords: Inherited metabolic diseases, Adult metabolic clinic, Treatment, Complications
Introduction
Inherited metabolic diseases (IMD) are genetic disorders
resulting from an enzyme defect and/or transport pro-
teins in metabolic pathways affecting proteins, fat, carbo-
hydrate metabolism or impaired organelle function. IMD
present as complex medical conditions involving mul-
tiple organ systems [1]. The most recent nosology of
IMD includes well over 1000 disorders [2]. Even though
they are individually rare, their collective prevalence is
estimated today at greater than 1:800 individuals [3]. Im-
provements in screening programs, disease awareness,
diagnostic tests and therapeutic interventions in IMD
have led to increasing patient survival and better prog-
nosis but also to the detection of milder or late-onset
forms that present in adulthood [4–7]. A recent survey
of the metabolic European reference network showed
that 50% of patients with IMD are adults (Scientific re-
port, Board annual meeting 2018, MetabERN).
In the past, IMD medicine has been considered as a
pediatric discipline and no formal training has been of-
fered for adult medicine. As a result, many of these pa-
tients are still under the care of their pediatricians as
young adults [8, 9]. As with other chronic illnesses, nu-
merous obstacles are known (i.e. lack of support system,
unfamiliarity with IMD, poor adherence to treatment)
which may interfere with the transition process [10, 11].
Little is known on long-term outcomes of childhood
IMD as many of the “first survivors” are only now ap-
proaching middle age. Exploring the long-term out-
comes of these patients is, nonetheless, important from
the viewpoint of developing the optimal treatment strat-
egy over a lifetime [12]. In order to meet this growing
demand, programs with a higher level of formal training
in adult IMD are underway in several countries [13]
leading to adult metabolic physicians specializing in
this new and expanding medical discipline [14]. How-
ever, according to a recent survey, most of the cen-
ters following adult patients with IMD felt the
current state of available education and training in
this field were insufficient [15].
In our country, an adult metabolic clinic was estab-
lished in 2013 at the Centre for Molecular Diseases of
the University Hospital of Lausanne and was extended
in 2015 by an affiliation with the Division of Endocrin-
ology, Diabetology, Hypertension and Nutrition of the
University Hospitals of Geneva. This study was intended
to establish a database of the current health of adult pa-
tients with IMD in order to better understand their clin-
ical course and to obtain a basis upon which to organize
the future health care provision for these patients.
Materials and methods
This study was approved by the Swiss Ethics Commit-
tees on research involving humans (Approval # 2017–
02328) and was registered at the U. S Clinical Trials
Registry as NCT03534752. All patients with a biochem-
ical and/or genetic diagnosis of IMD aged ≥16 years and
followed at the adult metabolic clinic from October 1st
2013 to December 31st 2017 were included. Patient were
divided into three groups according to the pathophysi-
ology and using a simplified classification of IMD: com-
plex molecule disorders, small molecule (intoxication)
disorders and energy defects disorders [16]. Electronic
and paper patient charts from the Division of Genetic
Medicine (Lausanne University Hospital) and the Div-
ision of Endocrinology, Diabetology, Hypertension and
Nutrition (Geneva University Hospitals) were reviewed
for clinical features, biochemical investigations, molecu-
lar genetic testing, treatment, number of hospitalizations,
complications of the disease and long-term outcome.
Dietary measures, special blend of amino acids formula,
vitamins, cofactors and any orphan drug were consid-
ered as specific treatment for IMD. Only complications
occurring during the time of analysis (from October 1st
2013 to December 31st 2017) and related to IMD were
included in the analysis.
A second analysis included all the patients referred
from October 1st 2013 to December 31st 2017 to the
Adult Metabolic Clinic for suspicion of IMD and for
whom further investigation had confirmed an IMD
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disease or not. We focused [1] on the reason for their re-
ferral (i.e. positive family history, suggestive symptoms
or biochemical abnormalities) and [2] the frequency of
confirmed IMD diagnosis, non-IMD diagnosis (other
cause) and unsolved cases. All data were entered in an
Excel file and were analyzed by research team members
(MN, KG and CT).
Statistical analysis
All data were analyzed using Excel statistical functions
for Office 365 for Mac and for Windows 2016. Fre-
quency was calculated for classification of patients ac-
cording to the metabolic subtype. Prevalence was
reported as percentage of the total group or subgroup of
patients depending on the studied outcome. Data for age
at the time of analysis were presented as mean ± SD.
Results
General
126 adult patients with IMD including 64 men (51%)
and 62 women (49%) were enrolled in the study. One
hundred (79%) of the patients had transitioned from the
pediatric metabolic clinics whereas 26 (21%) were re-
ferred from another specialty. The mean age (in years) at
the time of analysis for patients in the three subgroups
(complex molecules, small molecules and energy defects)
was 36.5 ± 14.9, 29.6 ± 11.0 and 33.6 ± 15.4, respectively.
An overview of the main results is summarized in
Table 1.
Disease frequencies
The most prevalent group of diseases was small mole-
cules disorders with 82 (65%) patients, followed by en-
ergy defect disorders with 29 (23%) patients and
complex molecules disorders with 15 (12%) patients.
Disorders of phenylalanine metabolism were the most
represented disease with 16 patients having classical
phenylketonuria (PKU) and seven mild hyperphenylala-
ninemia (supplementary Table 1). The most prevalent
group in complex molecule disorders was sphingolipido-
sis (lysosomal) with Gaucher and Niemann-Pick type B
diseases representing eight patients in total. Patients
with Fabry disease were not included in this study as
they were followed by a specific and separate clinic. The
most prevalent diseases in the energy defect disorders
were Chronic Progressive External Ophthalmoplegia
(CPEO) and Mitochondrial Encephalopathy with Lactic
Acidosis and Stroke-like episodes (MELAS) with a total
of 10 patients.
Age group at diagnosis and molecular analysis
Age group at diagnosis is reported in Table 1. Overall
the distribution of diagnosis by age was roughly equiva-
lent among the three age groups (infantile, 1 to 15 years,
over 16 years). In the subgroup analysis, the majority of
patients with small molecule disorders were diagnosed
during infancy (46%), while patients in the energy group
were diagnosed after the age of 16 years (66%). Age at
diagnosis in complex molecule disorders was widely









Number of patients 15 (12%) 82 (65%) 29 (23%) 126
Gender Male 10 35 19 64 51
Female 5 47 10 62 49
Age at diagnosis Infantile 0 38 2 40 32
1 to 15
years
9 23 8 40 32
Over 16
years
6 21 19 46 37
Transition from pediatric metabolic
clinic
11 70 19 100 79
New patients 4 12 10 26 21
Specific treatment 9 67 23 99 79
Identified pathogenic variant 10 29 24 63 50
Complications related to the disease 8 39 17 64 51
Hospitalized at least once 5 26 14 45 36
Hospitalized due to a metabolic
origin
6 15 12 33 73
Lost to follow-up 1 11 3 15 12
Deceased 1 1 0 2 2
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distributed between the different age groups. Factors
associated with diagnosis in adulthood were: [1] true
late-onset form of the disease. Some gene variants are
known to be associated with a milder, later onset pheno-
type (ex. the c.-32-13 T > G variant found in one of our
patient is reported in approx. 80–90% of late-onset
Pompe disease [17, 2] Delayed diagnosis of infantile
forms. Some of the adult patients diagnosed lately had
their first symptoms in infancy (i.e. splenomegaly in
Niemann-Pick B), and [3] genotypes known to be associ-
ated with variable clinical presentation, such as in mito-
chondrial disease. The diagnosis was based solely on
biochemical results in 50% of the cohort, while molecu-
lar genetic confirmation was obtained in the other half.
Of the 63 patients with genetic confirmation of the
pathogenic mutation, 29 (46%) had small molecule, 24
(38%) energy defect and 10 (16%) complex molecule
disorders.
Disease-related complications
During the study period (4 years, 2 months), 64 (51%) of
the 126 patients experienced disease-related complica-
tions. The number of complications by subgroup and
their characteristics are summarized in Table 2. The ma-
jority of the complications were due to worsening of
pre-existing complications (69%) followed by acute
metabolic decompensation (19%), and finally, newly de-
tected complications (13%). Among the 64 patients, 54
(84%) of them were receiving a specific treatment. In
total, 45 (36%) patients had at least one hospitalization
and for 33 (73%) of them it was for complications re-
lated to the IMD (i.e. acute metabolic decompensation,
cardiac decompensation, epilepsy, leukoencephalopathy).
Lost to follow-up and death
During the time of the study, 15 patients were lost to
follow-up. Five of them had been seen only once in
clinic and none of these patients had regular follow-up
primarily. Two of them relocated to another area with
an orderly transition to another adult metabolic clinic.
For two of them, it was due to lack of coordination be-
tween the different specialists in a multidisciplinary con-
text. Finally, six patients freely decided to discontinue
regular follow-up in our clinic. Factors associated with
loss of follow-up were poor adherence to treatment, in-
dependence from parental control after transition, inte-
gration in working life with limited availability, and
living at longer distance from our clinic. Two patients
passed away. One due to the natural history of the dis-
ease (Lesch-Nyhan syndrome) and one whose death out-
side the hospital was due to a possible cardiovascular
event (Niemann-Pick B).
New adult referrals
One hundred and thirty-eight (62 men and 76 women)
were referred to the metabolic clinic for a suspicion of
IMD. 133 patients were referred for symptoms and 5 for
a positive family history. The ones in which an IMD was
confirmed were included in the statistics of the general
results. Of the 138 referrals for IMD suspicion, a genetic
diagnosis was reached in 24 patients (17%): 19 with a
genuine IMD and 5 with a non-IMD genetic disease.
Three patients were found with a possibly disease-
related polymorphisms but not considered as genetic
disease (Table 3). Most of the diagnoses were made in
patients who had positive family history or neurological
symptoms with clear neurological findings (i.e. abnormal
electroneuromyography, elevated creatine kinase (CK),
signs of myopathy). Rare genetic but non-IMD diseases
were found using whole exome sequencing. Every new
diagnosis has resulted in genetic counseling. Neverthe-
less, a relatively low number of related individuals has
been identified. Two main reasons were identified: first,
adult patients often have less or no contact with their
families; and second, for adult individuals the clinical ob-
servation is often sufficient to rule out disease. Investiga-
tions were inconclusive for all the patients referred for
chronic fatigue syndrome, myalgia (with no elevation of
CK), chronic/joint pain but normal clinical examination
(data not shown).
Discussion
We undertook this study to obtain a global appreciation
of the current state of adult IMD medicine in the
French-speaking part of Switzerland. Some numerical re-
sults, as presented below, were in line with those ob-
tained in other countries and centres. However, we were
struck by what looked like a high burden of disease in
our patients, and this is the aspect we would like to
emphasize.
Which are the limitations of our study? Firstly, pa-
tients with Fabry disease were not included in this study
as they were followed at a parallel dedicated clinic. How-
ever, previous studies showed that Fabry disease was one
of the most prevalent IMD in adults with diagnosis al-
most exclusively in adulthood [12, 18]. This may affect
the interpretation of the disease frequencies and age
group at diagnosis in our cohort and its comparison
with previous studies. Secondly, some patients with IMD
in the French-speaking Switzerland may be followed by
other specialists or centres and therefore were not in-
cluded in our results; this may be particularly true for
individuals with less severe forms. Thirdly, classification
of IMD is variable according to the textbooks and litera-
ture. We based our criteria on a reference textbook for
inherited metabolic disease in adult [19], the Vademe-
cum Metabolicum [20] and the Saudubray classification
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Table 2 Characteristics of the complications related to the underlying inherited metabolic diseases arising during the time of the
study (total number of patients, N = 64)
Acute Metabolic decompensation (N = 12)
Group Disease Description Number (N)
2 Urea cycle disorders Hyperammoniemia 4
2 Leucinosis (Maple syrup urine disease) Encephalopathy with hyperleucinosis and Hyperammoniemia 1
2 Fructose-1,6-diphosphatase deficiency Hypoglycemia 1
2 Classical homocystinuria Hyperhomocysteinemia 4
3 HI/HA syndrome Hypoglycemia and hyperammoniemia 1
3 Carnitine palmitoyltransferase 2 Rhabdomyolysis 1
Novel complications (N = 8)
Group Disease Description
1 Pompe disease Dysphagia 1
1 X-ALD Myeloneuropathy 1
2 Arginosuccinic aciduria Dilated left ventricule 1
2 Fructose-1,6-diphosphatase deficiency Hepatomegaly 1
2 Galactosemia Osteopenia 1
2 Biotinidase deficiency Distal motor involvement 1
3 Kearns-Sayre syndrome Heart bifascicular block 1
3 Leigh syndrome Epilepsy 1
Worsening of pre-existing complication (N = 44)
Group Disease Description
1 Gaucher disease type I Fatigue 1
1 Niemann-Pick type B Restrictive lung disease, liver cirrhosis, portal hypertension, splenomegaly 4
1 Mucopolysaccharidosis type IVA Tracheal stenosis 1
1 Mucopolysaccharidosis type II Repetitive urinary tract and respiratory infection 1
2 Hereditary fructose intolerance Liver steatosis 1
2 Vitamin B12 unresponsive MMA Dystonia, kidney failure post transplant 2
2 Acute intermittent porphyria Depression 1
2 Wilson disease Dystonia, cirrhosis, depression 4
2 Mild hyperphenylalaninemia Behavioral disorders
2 Classical galactosemi Primary ovary insufficiency, optic atrophy, anxiety, osteopenia 5
2 Phenylketonuria Epilepsy 2
2 Classic homocystinuria Kidney failure, short bowel syndrome, osteoporosis 4
2 OAT deficiency Gyrate atrophy 1
2 Leucinosis Spastic diplegia 1
2 Cobalamin A deficiency Kidney failure 1
2 Cobalamin C deficiency Left ventricular dysfunction, mild mental retardation, bilateral retinopathy 2
2 Lesh-Nyhan syndrome Gastro-intestinal intolerance 1
3 CPEO Balance problems, myopathy, palpebral ptosis 4
3 MELAS Cardiomyopathy, diabetes, kidney failure 3
3 Mitochondrial complex III deficiency Fanconi syndrome 1
3 Ovario leucodystrophy related to AARS2 mutation Cognitive decline, myopathy 1
3 Glycogen storage disease type 3 Myalgia 2
3 KSS Diabetes 1
Abbreviations: CPEO chronic progressive external ophthalmoplegia, HI/HA hyperinsulinism/hyperammoniemia, KSS Kearns-Sayre Syndrome, MELAS
mitochondrial encephalopathy with lactic acidosis and stroke-like episodes, MMA methylmalonic acidemia, OAT ornithine aminotransferase, X-ALD X-linked
adrenoleucodystrophy
Group: 1) Complex molecules disorders, 2) Small molecules disorders, 3) Energy defect disorders
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[16, 21] but are aware that it may differ from other clas-
sifications such as the MetabERN diseases group (Euro-
pean Reference Network for Inherited Metabolic
Disorders) [22]. Fourthly, not all IMD are represented in
our cohort (i.e. congenital disorders of glycosylation,
some urea cycle disorders, and few subtypes of mucopo-
lysaccharidosis, glycogenosis and β-oxidation defect)
which also significantly biases the interpretation of the
results. For these reasons, we do not suggest that our
figures are necessarily applicable to other settings and
other countries. In spite of these shortcomings, we feel
that our study offers some insights that may be worthy
of reflection.
Comparison of the size of our clinic and its disease
distribution to other clinics around the world
In 2015, The SSIEM Adult Metabolic Physician Group
completed a survey of 15 centers worldwide with a total
number of 6182 adult patients [18]. The number of pa-
tients with confirmed metabolic diagnosis varied widely
between centers (from 10 to 1940). London had the
highest number of patients (1940), followed by Vancou-
ver (795) and Amsterdam (600). At that time, no Swiss
Center was included. Retrospectively our number of pa-
tients was close to the number of the Reference Centers
for Inherited Metabolic Diseases in Lille, France (126),
in Udine, Italy (117) and in Hamburg, Germany (155).
Table 3 Undiagnosed patients: reasons for referral and diagnosis
ID Reason for referral IEM diagnosis OMIM#
1 Myopathy, ptosis Mitochondrial disease (CPEO) 609,286
2 Epilepsy, ophthalmoplegia, ptosis Mitochondriopathy disease (ARPEO) 258,450
3 Myopathy, arthralgia, cognitive delay Myoadenylate deaminase deficiency 615,511
4 Myopathy, ovary insufficiency, cognitive decline, palpebral ptosis Mitochondrial disease (ovario leucodystrophy related to AARS2 variant) 615,889
5 Myopathy, respiratory insufficiency Heterozygous for Pompe late-onset disease (2nd variant not found) 232,300
6 Myopathy, respiratory insufficiency Pompe late-onset disease 232,300
7 Myopathy, ophthalmoplegia, ptosis Mitochondrial disease (CPEO) 609,286
8 Pulmonary embolism Homocystinuria due to CBS deficiency 236,200
9 Intestinal ischemic thrombosis, pulmonary embolism Homocystinuria due to CBS deficiency 236,200
10 Myopathy, ptosis Mitochondrial disease (KSS) 530,000
11 Biochemical hypermethioninemia, cognitive delay Methionine adenosyltransferase I/III deficiency 250,850
12 Progressive myelopathy X-linked AMN 300,100
13 Splenomegaly, liver cirrhosis, bone lesions Niemann-Pick type B 607,616
14 Hypoglycemia, hyperammoniemia HI/HA syndrome 606,762
15 Positive FHx for OTC OTC deficiency 311,250
16 Positive FHx for CBS deficiency Homocystinuria due to CBS deficiency 236,200
17 Positive FHx for CBS deficiency Homocystinuria due to CBS deficiency 236,200
18 Positive FHx for CBS deficiency Homocystinuria due to CBS deficiency 236,200
19 Positive FHx for CBS deficiency Homocystinuria due to CBS deficiency 236,200
ID Reason for referral Other Genetic diagnosis
20 Spastic paraparesis, cognitive delay Spastic paraparesis related to SPG11 variant 604,360
21 Cerebral calcification, leukoencephalopathy Nasu-Hakola syndrome (PLOSL) 618,193
22 Peripheric weakness, ataxia, ophthalmoplegia Autosomal dominant spinocerebellar ataxia 5 600,224
23 Familial neuropathy, muscle weakness Charcot-Marie Tooth related to LRSAM1 variant 614,436
24 Cognitive decline, peripheric neuropathy, polyglucosan bodies Charcot-Marie Tooth related to HARS1 variant 616,625
ID Reason for referral Possibly related polymorphisms
25 Mild elevation of homocysteine MTHFR polymorphism (compound heterozygous) NA
26 Mild elevation of homocysteine, venous thrombosis MTHFR polymorphism (compound heterozygous) NA
27 Recurrent pregnancy loss MTHFR polymorphism (compound heterozygous) NA
Abbreviations: ARPEO: autosomal recessive progressive external ophalmoplegia; AMN, adrenomyeloneuropathy; CPEO: chronic progressive
external ophthalmoplegia; CBS: cystathionine-β synthase deficiency; FHx: family history; HI/HA, hyperinsulinism/hyperammoniemia; ID; identity
number, KSS: Kearns-Sayre Syndrome; MTHFR, methylenetetrahydrofolate reductase; NA: not applicable; OMIM: online mendelian inheritance in
man; OTC, ornithine transcarbamylase; PLOSL, polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy; X-ALD,
X-linked adrenoleucodystrophy
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Considering that the French-speaking part of
Switzerland and the city of Hamburg both had a popula-
tion of nearly 2 million in 2018, the rate of attendance is
similar between these two clinics, confirming the plausi-
bility of our data. As expected, the most frequent dis-
order was PKU (including hyperphenylalaninemia),
representing 23 (18.3%) cases. This frequency is close to
the Report of the SSIEM adult Group (20.6%) and a
study from Perez-Lopez et al. (21.6%) where 500 cases of
adult patients with IMD from Reference Centers in
Spain were reviewed [12]. The high prevalence of PKU
may also be due to the fact that it has been the first dis-
order included in newborn screening programs [23]. The
prevalence of the other IMD in this study is comparable
to previous studies, notably with amino acid (protein)
metabolism disorders being the most prevalent group
[18]. The LSD group was underrepresented as our co-
hort did not include Fabry patients.
IMD diagnosed in adulthood account for more than 30%
of all diagnoses
Thirty-seven % of the patients were diagnosed after
16 years of age. This observation was close to the
SSIEM adult group report (45.7%) [18] and included
mainly patients from the energy defect disease group
and storage disorders. Adult-onset is frequent in
mitochondrial disease where individual level of het-
eroplasmy and variable environment can trigger the
disease at any age. In contrast, the majority of the
patients in the small molecule disorders group were
diagnosed in the infantile period which is likely ex-
plained by newborn screening and the frequent onset
of symptoms in the neonatal period. Of note, many
of our historical patients had been diagnosed solely
on biochemical grounds; with the advent of quasi-
universal application of next-generation sequencing
techniques, the recognition of variant forms with ju-
venile or adult onset will increase significantly [24,
25]. Here, it must be remarked that many of these
“adult” diagnoses were made because of astute obser-
vations or intuitions of individual physicians; we sus-
pect that a large number of individuals still go
unrecognized. Awareness of the indication for and
the availability of genetic testing remains fragmen-
tary among physicians caring for adult patients.
More than 50% of patients present with medical
complications
More than half of the patients developed medical
complications during the time of the study. Specific
IMD, particularly those involving energy deficiency
(mitochondrial diseases) and storage disorders, can
present with dysfunction of different systems, contrib-
uting to complications. While we did not formally
measured attendance and compliance, most of the pa-
tients attended the clinic regularly (as shown by the
lost to follow-up data). Some of the patients, mainly
from the small molecule disorder group, were suscep-
tible to acute metabolic decompensation, which re-
quired urgent hospital admission for correction of the
metabolic derangement. Reasons for decompensation
were in line with known triggers such as infection,
non-adherence to treatment, or prolonged exercise
[26]. Unfortunately, we observed several complications
in patients for whom only conservative treatment is
available with no disease-specific alternatives such as
enzyme replacement therapy or other.
The challenge continues after transition from pediatric to
adult care
The transition process has been effective for the majority
of patients in our cohort however a minority of patients
has been lost to follow-up thereafter, highlighting that
this period is fragile and needs careful attention such as
described previously for other genetic and/or endocrine
conditions [11, 27, 28]. In summary, the overall pattern
emerging from these observations is the following: pa-
tients diagnosed in the neonatal or paediatric period
benefit from improved therapy today as compared to 50
years ago and thus more patients reach adolescence and
adulthood; however these patients must go through a
transition process that paves the way to adulthood and
its new challenges. In addition, there is a growing num-
ber of patients who are diagnosed with an IMD in adult
age. As adults, all these patients may enjoy periods of
stability but decompensations are possible at any time
and late-onset complications appear as the patients age
and the chronic genetic disease continues to exact its
toll.
Ongoing efforts to coordinate diagnosis and care of
individuals with IMD
Newborn screening for various IMD has already existed
in Switzerland for 50 years [29]; and in 2017, Switzerland
was considered to have the third best standard of health-
care in the world [30]. Despite this remarkable track rec-
ord, the observations above indicate that there is much
room for improvement. Specific programmes for rare
diseases have been or are being implemented in several
European countries. Most of these programmes include
a specific section on IMD. In Switzerland, The National
Coordination for Rare Diseases (Kosek) is mandated
with the establishment of networks to improve the care
of individuals affected by rare diseases. One of the pilot
groups within the Kosek is focused on IMD. One of the
requisites of the networking progress is to make sure
that dedicated centers meet high standards of
organization and accountability [31]. Ultimately, national
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recognition should enable reference centers to integrate
European reference networks [22]. Nevertheless, we
would like to suggest that national coordination will not
work unless the individual centers are improved and
strengthened.
Conclusions
In the twenty-first century, we welcome the fact that im-
proved diagnosis and treatment are making IMD mortal-
ity a relic of the past, giving way to a growing adult
population. However these advances also bring chal-
lenges for medicine and society. In spite of the limita-
tions discussed above, this retrospective study may give
some indications on the outcome of these patients and
indicate where the health system might be improved fur-
ther: [1] adults with IMD are clearly an emerging popu-
lation in Switzerland and may soon outnumber the
pediatric population. Both children and adults with IMD
require specific management and expertise from the
health care providers, but the requirements are different
and the setting is different (pediatric clinics vs. adult
clinics), [2] as more than half of our patients developed
organ-specific complications, a multidisciplinary team
and disease-specific personalized health plans are neces-
sary to monitor target organs and [3] as no patient is
protected from metabolic decompensations, IMD clinics
must be connected to tertiary hospitals offering intensive
care units as well as availability of specific drugs. Hence
the need for coordination of the management of these
rare diseases at the national, and ideally international,
level.
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